New Novartis: Holding subsidiaries and affiliates jointly signed a strategic cooperation and authorization agreement with AstraZeneca.

Announcement from Xinnorway: the company's controlling subsidiary Jushi Biology, and the company's related parties Shiyao Group and Zhongqi Pharmaceutical, signed a "strategic cooperation and authorization agreement" with AstraZeneca on January 29, and will carry out comprehensive strategic cooperation with AstraZeneca in the field of innovative peptide molecule discovery and long-acting delivery products. The subject of this agreement is the innovative long-acting peptide drugs developed by the licensor based on the long-acting delivery technology platform and peptide drug discovery platform it owns, including a clinically ready project SYH2082, as well as three preclinical stage research projects with different mechanisms of action. The two parties will also cooperate on four additional projects based on these platforms.